Impel Neuropharma's nose-to-brain drug delivery method sent a small peptide molecule into the brain in a seven-patient trial, the company's chief scientist said. The technology could have applications in central nervous system disorders and pain relief. Angel investors, the NIH, the Pentagon and Washington state's Life Sciences Discovery Fund provided support for the project.
Nose-to-brain drug delivery method works in early trial
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.